FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200569817> ?p ?o ?g. }

• W4200569817 endingPage "11" @default.
• W4200569817 startingPage "11" @default.
• W4200569817 abstract "Abstract Introduction: Many children with sickle cell anemia (SCA) require blood transfusions, which carry risks and utilize a scarce resource globally, particularly in Africa. Realizing Effectiveness Across Continents with Hydroxyurea (REACH, NCT01966731) has documented the safety, feasibility, and benefits of hydroxyurea for children with SCA living in sub-Saharan Africa. In REACH, hydroxyurea escalated to maximum tolerated dose (MTD) significantly decreased vaso-occlusive events, malaria, and death; transfusions were decreased by ~70% over 30 months of treatment when compared to the 2-month screening period. Characterizing how hydroxyurea reduces transfusion needs in REACH could contribute to improved clinical understanding and lead to better outcomes, a decreased transfusion burden, and preservation of the blood supply in these limited-resource settings. Methods: Transfusions were recorded prospectively in the REACH REDCap electronic database. Using time-varying predictors and landmark analysis, transfusions during screening and treatment were analyzed by clinical site, calendar month, age, gender, splenomegaly, hydroxyurea dose, MTD status, baseline and latest laboratory values (Hemoglobin, MCV, HbF, absolute neutrophil count, and platelets, all measured at least 30 days prior to the transfusion), alpha thalassemia trait, and G6PD deficiency. Incidence rate ratios (IRR) were calculated for treatment periods compared to screening. Univariate relationships were assessed using the Anderson-Gill model, plus multiple regression to estimate Hazard Ratios (HR) with 95% confidence intervals (CI's). Results: A total of 635 children with SCA enrolled in REACH, and 606 started hydroxyurea treatment. During screening, 48 transfusions were given to 43 children, and during the treatment phase 405 transfusions were administered to 214 children over an average treatment time of 5.2 ± 1.3 years. The transfusion rate was 43.3 per 100 patient-years during screening, which decreased to 22.0 per 100 patient-years during the initial fixed dose treatment period (IRR = 0.50; 95%CI = 0.35-0.74, p&lt;0.001 compared to screening) and then decreased further to 12.1 per 100 patient-years during the dose escalation period (IRR = 0.28; 95%CI = 0.21-0.39, p&lt;0.001 compared to screening; IRR = 0.54; 95%CI = 0.43-0.73, p&lt;0.001 compared to fixed-dose). For every 100 children treated for a year with hydroxyurea during dose escalation, there were 31.4 fewer transfusions compared to the untreated screening period. Comparison of the indications for transfusion between the screening and treatment periods revealed transfusions administered for anemia decreased from a rate of 26.1 to 5.1 per 100 patient-years (p&lt;0.001), while transfusions for malaria trended toward a decrease from 7.2 to 3.8 per 100 patient-years (p=0.08). Lower transfusion rates on hydroxyurea were associated with higher hemoglobin concentration (HR = 0.72 per 1g/dL increase; 95%CI = 0.65-0.78, p &lt;0.0001) and higher HbF levels (HR = 0.80 per 10% increase, 95%CI = 0.69-0.92, p=0.0071). Those with palpable splenomegaly had higher transfusion rates (HR = 1.58, 95%CI = 1.22-2.03, p=0.0094). Age, gender, alpha thalassemia trait, G6PD deficiency, and neutrophil count were not associated with differences in transfusion rates. Conclusion: Hydroxyurea significantly reduces blood transfusion administration in children with SCA in sub-Saharan Africa, especially when escalated to MTD. Transfusions for the sole indication of anemia decreased significantly on hydroxyurea treatment, likely due to higher treatment-associated hemoglobin levels and decreased hemolysis, and transfusions for malaria also trended toward a decrease. Splenomegaly remains a risk factor for transfusions despite hydroxyurea treatment. Overall, increased access to and implementation of hydroxyurea treatment for children with SCA across sub-Saharan Africa may not only improve individual patient outcomes through reduction in anemia, transfusion burden, and transfusion-associated complications including infections, but may also to help preserve the scarce blood supply for the benefit of the larger population. Disclosures Aygun: Global Blood Therapeutics: Consultancy; Patient Centered Outcomes Research Institute: Research Funding; National Heart, Lung, Blood Institute: Research Funding; National Institute of Nursing Research: Research Funding; bluebird bio, Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding. Stuber: ASH Research Collaborative: Consultancy. Ware: Bristol Myers Squibb: Research Funding; Addmedica: Research Funding; Hemex Health: Research Funding; Nova Laboratories: Research Funding; Novartis: Other: DSMB Chair; Editas: Other: DSMB Chair." @default.
• W4200569817 created "2021-12-31" @default.
• W4200569817 creator A5000385666 @default.
• W4200569817 creator A5000445059 @default.
• W4200569817 creator A5015470622 @default.
• W4200569817 creator A5017286562 @default.
• W4200569817 creator A5024290777 @default.
• W4200569817 creator A5028638805 @default.
• W4200569817 creator A5040752648 @default.
• W4200569817 creator A5045317464 @default.
• W4200569817 creator A5050932952 @default.
• W4200569817 creator A5066612645 @default.
• W4200569817 creator A5070268746 @default.
• W4200569817 creator A5080985679 @default.
• W4200569817 date "2021-11-05" @default.
• W4200569817 modified "2023-10-18" @default.
• W4200569817 title "Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience" @default.
• W4200569817 doi "https://doi.org/10.1182/blood-2021-146632" @default.
• W4200569817 hasPublicationYear "2021" @default.
• W4200569817 type Work @default.
• W4200569817 citedByCount "0" @default.
• W4200569817 crossrefType "journal-article" @default.
• W4200569817 hasAuthorship W4200569817A5000385666 @default.
• W4200569817 hasAuthorship W4200569817A5000445059 @default.
• W4200569817 hasAuthorship W4200569817A5015470622 @default.
• W4200569817 hasAuthorship W4200569817A5017286562 @default.
• W4200569817 hasAuthorship W4200569817A5024290777 @default.
• W4200569817 hasAuthorship W4200569817A5028638805 @default.
• W4200569817 hasAuthorship W4200569817A5040752648 @default.
• W4200569817 hasAuthorship W4200569817A5045317464 @default.
• W4200569817 hasAuthorship W4200569817A5050932952 @default.
• W4200569817 hasAuthorship W4200569817A5066612645 @default.
• W4200569817 hasAuthorship W4200569817A5070268746 @default.
• W4200569817 hasAuthorship W4200569817A5080985679 @default.
• W4200569817 hasBestOaLocation W42005698172 @default.
• W4200569817 hasConcept C120665830 @default.
• W4200569817 hasConcept C121332964 @default.
• W4200569817 hasConcept C126322002 @default.
• W4200569817 hasConcept C187212893 @default.
• W4200569817 hasConcept C203014093 @default.
• W4200569817 hasConcept C207103383 @default.
• W4200569817 hasConcept C2777799968 @default.
• W4200569817 hasConcept C2778048844 @default.
• W4200569817 hasConcept C2778248108 @default.
• W4200569817 hasConcept C2778620579 @default.
• W4200569817 hasConcept C2779134260 @default.
• W4200569817 hasConcept C2780014101 @default.
• W4200569817 hasConcept C44249647 @default.
• W4200569817 hasConcept C61511704 @default.
• W4200569817 hasConcept C71924100 @default.
• W4200569817 hasConceptScore W4200569817C120665830 @default.
• W4200569817 hasConceptScore W4200569817C121332964 @default.
• W4200569817 hasConceptScore W4200569817C126322002 @default.
• W4200569817 hasConceptScore W4200569817C187212893 @default.
• W4200569817 hasConceptScore W4200569817C203014093 @default.
• W4200569817 hasConceptScore W4200569817C207103383 @default.
• W4200569817 hasConceptScore W4200569817C2777799968 @default.
• W4200569817 hasConceptScore W4200569817C2778048844 @default.
• W4200569817 hasConceptScore W4200569817C2778248108 @default.
• W4200569817 hasConceptScore W4200569817C2778620579 @default.
• W4200569817 hasConceptScore W4200569817C2779134260 @default.
• W4200569817 hasConceptScore W4200569817C2780014101 @default.
• W4200569817 hasConceptScore W4200569817C44249647 @default.
• W4200569817 hasConceptScore W4200569817C61511704 @default.
• W4200569817 hasConceptScore W4200569817C71924100 @default.
• W4200569817 hasIssue "Supplement 1" @default.
• W4200569817 hasLocation W42005698171 @default.
• W4200569817 hasLocation W42005698172 @default.
• W4200569817 hasOpenAccess W4200569817 @default.
• W4200569817 hasPrimaryLocation W42005698171 @default.
• W4200569817 hasRelatedWork W2013062939 @default.
• W4200569817 hasRelatedWork W2023570989 @default.
• W4200569817 hasRelatedWork W2088088253 @default.
• W4200569817 hasRelatedWork W2103972186 @default.
• W4200569817 hasRelatedWork W2128750304 @default.
• W4200569817 hasRelatedWork W2388827573 @default.
• W4200569817 hasRelatedWork W2390756468 @default.
• W4200569817 hasRelatedWork W2409957712 @default.
• W4200569817 hasRelatedWork W4362450692 @default.
• W4200569817 hasRelatedWork W3088975555 @default.
• W4200569817 hasVolume "138" @default.
• W4200569817 isParatext "false" @default.
• W4200569817 isRetracted "false" @default.
• W4200569817 workType "article" @default.